Perosphere, Daiichi Sankyo deal

Daiichi Sankyo will co-sponsor a Phase I trial evaluating Perosphere's PER977 to reverse the anticoagulant activity of Daiichi Sankyo's edoxaban. PER977 is a small molecule that binds with heparin a...